Protective Efficacy of Centralized and Polyvalent Envelope Immunogens in an Attenuated Equine Lentivirus Vaccine

PLoS Pathogens

Volumn 11, Issue 1, 2015, Pages 1-14

  Craigo, Jodi K ^a,b   Ezzelarab, Corin ^a,b   Cook, Sheila J ^c   Liu, Chong ^c   Horohov, David ^c   Issel, Charles J ^c   Montelaro, Ronald C ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; ENVELOPE IMMUNOGEN; LENTIVIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; LIVE VACCINE; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; EQUINE INFECTIOUS ANEMIA VIRUS; IMMUNOGENICITY; NONHUMAN; PHYLOGENY; PONY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS STRAIN; AMINO ACID SEQUENCE; ANIMAL; ANTIGENIC VARIATION; EQUINE INFECTIOUS ANEMIA; GENETIC VARIABILITY; GENETICS; HORSE; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; TREATMENT OUTCOME;

ANIMALIA; EQUINE INFECTIOUS ANEMIA VIRUS; EQUINE LENTIVIRUSES; LENTIVIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENIC VARIATION; BASE SEQUENCE; EQUINE INFECTIOUS ANEMIA; GENETIC VARIATION; HORSES; INFECTIOUS ANEMIA VIRUS, EQUINE; MOLECULAR SEQUENCE DATA; PHYLOGENY; TREATMENT OUTCOME; VACCINES, ATTENUATED; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 84923849504     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004610     Document Type: Article

References (63)

1. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354–2360.
2. Anastassopoulou CG, Kostrikis LG, (2006) Global genetic variation of HIV-1 infection. Curr HIV Res 4: 365–373.
3. Brander C, Frahm N, Walker BD, (2006) The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol 18: 430–437.
4. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, et al. (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. BrMedBull 58: 19–42.
5. Mullins JI, Jensen MA, (2006) Evolutionary dynamics of HIV-1 and the control of AIDS. Curr Top Microbiol Immunol 299: 171–192.
6. Liao HX, Tsao CY, Alam SM, Muldoon M, Vandergrift N, et al. (2013) Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol 87: 4185–4201.
7. Mullins JI, Nickle DC, Heath L, Rodrigo AG, Learn GH, (2004) Immunogen sequence: the fourth tier of AIDS vaccine design. Expert Rev Vaccines 3: S151–159.
8. Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, et al. (2003) Consensus and ancestral state HIV vaccines. Science 299: 1515–1518 author reply 1515-1518.
9. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, et al. (2005) Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 79: 1154–1163.
10. Doria-Rose NA, Learn GH, Rodrigo AG, Nickle DC, Li F, et al. (2005) Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 79: 11214–11224.
11. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, et al. (2007) Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360: 218–234.
12. Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, et al. (2006) Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 352: 438–449.
13. Santra S, Muldoon M, Watson S, Buzby A, Balachandran H, et al. (2012) Breadth of cellular and humoral immune responses elicited in rhesus monkeys by multi-valent mosaic and consensus immunogens. Virology 428: 121–127.
14. Santra S, Korber BT, Muldoon M, Barouch DH, Nabel GJ, et al. (2008) A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A 105: 10489–10494.
15. Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, et al. (2006) A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353: 268–282.
16. Gao F, Liao HX, Hahn BH, Letvin NL, Korber BT, et al. (2007) Centralized HIV-1 envelope immunogens and neutralizing antibodies. Curr HIV Res 5: 572–577.
17. Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, et al. (2006) Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 80: 6745–6756.
18. Eugene HS, Pierce-Paul BR, Cragio JK, Ross TM, (2013) Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge. Virol J 10: 102.
19. Mcburney SP, Ross TM, (2009) Human immunodeficiency virus-like particles with consensus envelopes elicited broader cell-mediated peripheral and mucosal immune responses than polyvalent and monovalent Env vaccines. Vaccine 27: 4337–4349.
20. Montelaro RC, Ball JM, Rushlow K (1993) Equine retroviruses. In: Levy JA, editor. The Retroviridae. New York, N.Y.: Plenum Press. pp. 257–360.
21. Harrold SM, Cook SJ, Cook RF, Rushlow KE, Issel CJ, et al. (2000) Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 74: 3112–3121.
22. Hammond SA, Li F, Mckeon BM, SrCook SJ, Issel CJ, et al. (2000) Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 74: 5968–5981.
23. Kono Y, Hirasawa K, Fukunaga Y, Taniguchi T, (1976) Recrudesence of equine infectious anemia by treatment with immunosuppressive drugs. Nat Inst Anim Hlth Quart 16: 8–15.
24. Craigo JK, Montelaro RC, (2013) Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity. Viruses 5: 2963–2976.
25. Craigo JK, Montelaro RC, (2011) Equine Infectious Anemia Virus Infection and Immunity: Lessons for Aids Vaccine Development. Future Virol 6: 139–142.
26. Craigo JK, Montelaro RC (2008) Equine Infectious Anemia Virus (Retroviridae). Encyclopedia of Virology. Third ed. Oxford: Elsevier. pp. 167–174.
27. Craigo JK, Montelaro RC (2010) Lentivirus Tropism and Disease. In: Desport M, editor. Lentiviruses and Macrophages: Molecular and Cellular Interactions: Horizon Academic Press. pp. 1–23.
28. Craigo JK, Ezzelarab C, Cook SJ, Chong L, Horohov D, et al. (2013) Envelope determinants of equine lentiviral vaccine protection. PLoS ONE 8: e66093.
29. Craigo JK, Montelaro RC, (2010) EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy. Curr HIV Res 8: 81–86.
30. Montelaro RC, Cole KS, Hammond SA, (1998) Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS ResHumRetroviruses 14 Suppl 3: S255–S259.
31. Craigo JK, Durkin S, Sturgeon TJ, Tagmyer T, Cook SJ, et al. (2007) Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine 25: 834–845.
32. Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, et al. (2005) Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol 79: 2666–2677.
33. Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, et al. (2003) A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 77: 7244–7253.
34. Craigo JK, Zhang B, Barnes S, Tagmyer TL, Cook SJ, et al. (2007) Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci U S A 104: 15105–15110.
35. Montelaro RC, Wigzell H, (1995) AIDS 1995. Vaccines and immunology: overview. AIDS 9 Suppl A: S111–S112.
36. Mills J, Desrosiers RC, Rud E, Almond N, (2000) Live Attenuated HIV Vaccines: A Proposal for Further Research and Development. AIDS ResHumRetroviruses 16: 1453–1461.
37. Uhl EW, Heaton-Jones TG, Pu R, Yamamoto JK, (2002) FIV vaccine development and its importance to veterinary and human medicine: a review. FIV vaccine 2002 update and review. VetImmunolImmunopathol 90: 113–132.
38. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, et al. (2006) HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7: 19–23.
39. Craigo JK, Barnes S, Cook SJ, Issel CJ, Montelaro RC, (2010) Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease. Vaccine 28: 8095–8104.
40. Tagmyer TL, Craigo JK, Cook SJ, Even DL, Issel CJ, et al. (2008) Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J Virol 82: 4052–4063.
41. Tagmyer TL, Craigo JK, Cook SJ, Issel CJ, Montelaro RC, (2007) Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J Gen Virol 88: 1324–1336.
42. Leroux C, Craigo JK, Issel CJ, Montelaro RC, (2001) Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J Virol 75: 4570–4583.
43. Leroux C, Issel C, Montelaro RC, (1997) Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol 71: 9627–9639.
44. Craigo JK, Sturgeon TJ, Cook SJ, Issel CJ, Leroux C, et al. (2006) Apparent elimination of EIAV ancestral species in a long-term inapparent carrier. Virology 344: 340–353.
45. Cook RF, Cook SJ, Berger SL, Leroux C, Ghabrial NN, et al. (2003) Enhancement of equine infectious anemia virus virulence by identification and removal of suboptimal nucleotides. Virology 313: 588–603.
46. Craigo JK, Ezzelarab C, Montelaro RC, (2012) Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus. J Virol Methods 185: 221–227.
47. Howe L, Leroux C, Issel CJ, Montelaro RC, (2002) Equine Infectious Anemia Virus Envelope Evolution In Vivo during Persistent Infection Progressively Increases Resistance to In Vitro Serum Antibody Neutralization as a Dominant Phenotype. The Journal of Virology 76: 10588.
48. Li F, Puffer BA, Montelaro RC, (1998) The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J Virol 72: 8344–8348.
49. Lichtenstein DL, Issel CJ, Montelaro RC, (1996) Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus. J Virol 70: 3346–3354.
50. Issel CJ, Horohov DW, Lea DF, Adams WV, JrHagius SD, et al. (1992) Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol 66: 3398–3408.
51. Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC, (1997) Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 71: 3840–3852.
52. Weaver EA, Camacho ZT, Gao F, (2010) Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions. AIDS Res Hum Retroviruses 26: 577–584.
53. Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM, (2012) Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol 19: 128–139.
54. Giles BM, Crevar CJ, Carter DM, Bissel SJ, Schultz-Cherry S, et al. (2012) A computationally optimized hemagglutinin virus-like particle vaccine elicits broadly reactive antibodies that protect nonhuman primates from H5N1 infection. J Infect Dis 205: 1562–1570.
55. Giles BM, Ross TM, (2012) Computationally optimized antigens to overcome influenza viral diversity. Expert Rev Vaccines 11: 267–269.
56. Giles BM, Ross TM, (2011) A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29: 3043–3054.
57. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, et al. (2007) Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360: 218–234.
58. Swofford DL (2001) PAUP: Phylogenetic Analysis Using Parsimony and Other Methods. Sunderlan, MA: Sinauer Associates.
59. Leroux C, Cadore JL, Montelaro RC, (2004) Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us? Vet Res 35: 485–512.
60. Cook RF, Cook SJ, Li FL, Montelaro RC, Issel CJ, (2002) Development of a multiplex real-time reverse transcriptase-polymerase chain reaction for equine infectious anemia virus (EIAV). J Virol Methods 105: 171–179.
61. Liu C, Cook FR, Cook SJ, Craigo JK, Even DL, et al. (2012) The determination of in vivo envelope-specific cell-mediated immune responses in equine infectious anemia virus-infected ponies. Vet Immunol Immunopathol 148: 302–310.
62. Ramakers C, Ruijter JM, Deprez RH, Moorman AF, (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339: 62–66.
63. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 25: 402–408.